Answers are grounded in this paper and cite their sources.
Every 6-month CGM measures in multiple-AAB-positive individuals are predictive of subsequent T1D, but less so than OGTT-derived variables. CGM may have feasibility advantages and be useful in some settings. However, our data suggest there is insufficient evidence to replace OGTT measures with CGM in the context of clinical trials.
No takes yet. Share an insight, caveat, or question.
Ylescupidez et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: